Parenchyma-sparing strategy and oncological prognosis in patients with colorectal cancer liver metastases

Background: Preliminary study results demonstrated parenchyma-sparing surgery (PSS) as an effective approach which allowed to remove colorectal cancer (CRC) metastatic lesions within the central liver cites and increased the probability of the liver re-resections. Methods: The prospective analysis re-evaluation of the 185 CRC patients surgical treatment has been performed. Results: An overall 5-year survival (OS) of the 185 enrolled patients was 43 +/- 7%, and the mean and median value for OS was 48.7 +/- 1.9% and 55.2 +/- 5 (95% CI: 44.4-66.1) months. The 5-year OS for CRC patients whose metastatic lesions were predominantly located within peripheral and central liver segments was 56 +/- 8% and 27 +/- 9%, respectively (p = 0.08). A 5-year disease-free survival (DFS) rates of patients with peripheral and central liver cites metastatic lesions were 31 +/- 7 % and 15 +/- 7%, p = 0,12. And the DFS median was 34.2 and 46.5 months for R-1v and R0 cohorts, respectively, p = 0.62. Conclusions: Parenchyma-sparing surgery should be a priority pathway for complex treatment of patients with deeply located lesions of the right liver lobe.

Automated summary

Parenchyma-sparing surgery is the preferred approach for treating patients with deeply located lesions in the right liver lobe. This surgical method not only increases the possibility of liver re-resection for colorectal cancer metastatic lesions within the central liver, but also improves the overall survival rate and disease-free survival rate for patients.